Health Care • Biotechnology: Pharmaceutical Preparations
$2.11 ▲ +0.00
(0.00%)
MKT CAP: $2.2M • VOL: 30.6K
52W L $2 52W H $320
ROARABLE / RQD
E • 32/100
PIOTROSKI
2 / 9
PPCB // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-06-30 | FY 2024
FILED 2024-06-30 | FY 2023
FILED 2023-06-30 |
|---|---|---|---|
| Revenue (Total Sales) | $0 | $0 | $0 |
| YoY Revenue Growth % | — | — | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$57.3M | -$1.5M | -$1.8M |
| Operating Margin % | — | — | — |
| Net Income (GAAP) | -$58.9M | -$1.8M | -$2.7M |
| EBITDA (Normalized) | — | — | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$405.2K | -$935.1K | -$1.1M |
| Capital Expenditures (CapEx) | — | — | — |
| Free Cash Flow (FCF) | -$405.2K | -$935.1K | -$1.1M |
| FCF Margin % | — | — | — |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | — | — | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $10.5M | -$4.2M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR PPCB.